Comparability of Trial Populations in Network Meta-Analyses Assessing Biologic Treatments in Moderate to Severe Plaque Psoriasis

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.1310
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Assessing the Relative Efficacy of Interleukin-17 and Interleukin-23 Targeted Treatments for Moderate-To-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of PASI Response

PLoS ONE
Multidisciplinary
2019English

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2019English

Cost Per Responder for Ixekizumab and Other Biologic Drugs Approved for the Treatment of Moderate-To-Severe Plaque Psoriasis in Italy

Global and Regional Health Technology Assessment
Health Policy
2019English

The Experience of Pain and Redness in Patients With Moderate to Severe Plaque Psoriasis

Journal of Dermatological Treatment
Dermatology
2015English

Efficacy and Safety of Biologic Agents and Tofacitinib in Moderate-To-Severe Ulcerative Colitis: A Systematic Overview of Meta-Analyses

United European Gastroenterology Journal
OncologyGastroenterology
2019English

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients With Moderate-To-Severe Plaque Psoriasis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

PSS14 Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Pss15 - Budget Impact Analysis of Apremilast in Patients With Moderate-To-Severe Plaque Psoriasis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy